期刊文献+

血清sRANKL/OPG比值在判断多发性骨髓瘤骨病中的意义 被引量:5

Significance of sRANKL/OPG Ratio in Diagnosis of Multiple Myeloma Bone Disease
下载PDF
导出
摘要 本研究探讨多发性骨髓瘤(MM)患者血清中可溶性核转录因子-κB受体活化因子的配体(sRANKL)和护骨蛋白(OPG)的水平与多发性骨髓瘤骨病(MBD)之间的关系。采用酶联免疫吸附法检测了42例初诊的MM病人(观察组)以及25例健康体检者(对照组)外周血清中sRANKL和OPG的水平以及破骨细胞代谢指标抗酒石酸酸性磷酸酶-5b(TRAP-5b)与Ⅰ型胶原蛋白羧基末端交联肽(CTP-Ⅰ)的水平,同时根据全身X光摄片判断MM患者骨损害情况并分析sRANKL/OPG比值与TRAP-5b、CTP-Ⅰ水平和骨损害发生及其程度之间的关系。结果发现:观察组患者血清中sRANKL水平升高(中位水平9.33μg/L),OPG水平下降(中位水平4.93μg/L),sRANKL/OPG比值明显升高(比值2.65),与对照组相比各对应指标之间的差异均具有显著性(p<0.05);MM患者血清中sRANKL/OPG比值与TRAP-5b(r=0.512,p<0.05)和CTP-Ⅰ(r=0.481,p<0.05)水平之间均存在相关性。将观察组患者按有无骨损害分组发现,骨损害组(29例)和无骨损害组(13例)的sRANKL/OPG比值分别为5.13和1.12,有骨损害组的比值明显升高(p<0.05);如果按骨损害程度分组还发现,sRANKL/OPG比值与骨损害程度密切相关(r=0.445,p<0.05),但不同临床分型和不同临床分期(ISS分期)的MM患者之间,血清sRANKL/OPG比值的差异均无统计学意义(p>0.05)。结论:MM患者血清中sRANKL/OPG比值明显升高,不仅与破骨细胞代谢增强有关,还与骨损害的发生及其程度相关,所以sRANKL/OPG比值可作为判断MBD的一个参考指标。 This study was purposed to investigate the relationship between the levels of soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) in serum of the patients with multiple myeloma (MM) and multiple myeloma bone disease (MBD). The serum levels of sRANKL, OPG, tartrate-resistant acid phosphatase-5b(TRAP-5b) and C-terminal telopeptide of collagen Ⅰ (CTP-Ⅰ ) which both are indexes for metabolism of osteoclast (OC) in newly diagnosed MM patients ( n = 42, experimental group) and healthy persons ( n = 25, control group) were detected by enzyme-linked immunosorbent assay. The roentgenography was used to determine bone damage in MM patients at the same time. According to these results acquired, the correlation of sRANKL/OPG ratio with levels of TRAP-5b,/CTP-Ⅰ, the incidence and degree of bone destruction were analyzed. The results indicated that the level of sRANKL(median value 9. 33 μg/L ) increased and level of OPG (median value 4. 93 μg/L) decreased and the sRANKL/OPG ratio (2. 65 ) increased significantly in experimental group. Compared with control group, the differences in all the corresponding indicators were statistically significant (p 〈 0.05 ). The sRANKL/OPG ratio was closely related to levels of TRAP-5b ( r = 0.512 ,p 〈 0.05 ) and CTP-Ⅰ ( r = 0.481,p 〈 0.05 ) in MM patients. After all patients in experimental groups were divided into group with bone destruction (n = 29) and without bone destruction (n = 13 ), the sRANKL/OPG ratio in the group with bone destruction was 5.13 and much higher than that in group without bone destruction ( 1. 12 ) (p 〈 0. 05 ). A close correlation between the sRANKL/OPG ratio and degree of bone destruction ( r = 0. 445, p 〈 0.05 ) was acquired when all MM patients were divided into three groups according to degree of bone destruction, but no difference between the ratio and clinical classification and International Staging System (ISS) in MM patients was found. It is concluded that the sRANKL/OPG ratio in serum of MM patients is significantly elevated, which may be closely related to increase metabolism of OC along with the incidence and degree of bone destruction. In short, the sRANKL/OPG ratio can be used as a reference index for the diagnosis of MBD.
出处 《中国实验血液学杂志》 CAS CSCD 2010年第2期376-380,共5页 Journal of Experimental Hematology
基金 国家自然科学基金项目(30670997) 广东省科技计划项目(B080703055) 中山大学附属一院优秀青年人才支持计划项目(18700108)
关键词 多发性骨髓瘤骨病 核转录因子-κB受体活化因子 护骨蛋白 破骨细胞 multiple myeloma bone disease receptor activator of nuclear factor kappa B osteoprotegerin osteoclast
  • 相关文献

参考文献14

  • 1Vitovski S, Phillips JS, Sayers J, et al. Investigating the interaction between osteoprotegerin and receptor activator of NF- kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem, 2007 ;282 ( 43 ) : 31601 - 31609.
  • 2许多荣,陈惠珍,王荷花,李娟,罗绍凯.核转录因子κB受体激活剂可能通过新的信号途径调节破骨细胞分化[J].中国实验血液学杂志,2009,17(3):607-611. 被引量:2
  • 3朱恒,江小霞,毛宁.破骨细胞参与调控骨髓造血微环境[J].中国实验血液学杂志,2007,15(6):1312-1316. 被引量:6
  • 4Brunetti G, Colucci S, Rizzi R, et al. The role of OPG/TRAIL complex in multiple myeloma., the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease. Ann NY Acad Sci,2006;1068:334 -340.
  • 5Roodman GD, Choi SJ. MIP-1 alpha and myeloma bone disease. Cancer Treat Res, 2004,118 : 83 - 100.
  • 6张之南,沈悌.血液病诊断及疗效标准.第三版.北京:科学出版社.2008:232-235.
  • 7Alexandrakis MG, Passam FH, Malliaraki N, et al. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta, 2002 ;325 ( 1 -2) :51 -57.
  • 8Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007;65 (12 Pt2) :S147 -151.
  • 9Yata K, Abe M, Matsumoto T. Mechanisms for formation of myeloma bone disease. Clin Calcium,2008 ; 18 (4) :438 - 446.
  • 10鲍立,黄晓军.SDF-1/CXCR4与多发性骨髓瘤溶骨性病变的关系[J].中国实验血液学杂志,2008,16(2):442-446. 被引量:4

二级参考文献66

  • 1Abe M,Hiura K,Wilde J,et al.Role for macrophage inflammatory protein MIP-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma.Blood,2002,100:2195-2202
  • 2Inoue J,Ishida T,Tsukamoto N,et al.Tumor necrosis factor receptor-associated factor(TRAF)family:adapter proteins that mediate cytokine signaling.Exp Cell Res,2000,254:14-24
  • 3Xu D,Shi Z,McDonald J,et al.Development of a chimaeric receptor appmach to study signaling by tumour necrosis factor family members.Biochem J,2004,383(Pt2):219-225
  • 4Liu W,Xu D,Yang H,et al.Functional identification of three receptor activator of NF-kappa B cytoplasmic motifs mediating osteoclast differentiation and function.J Biol Chem,2004,279:54759-54769
  • 5Mountazios G,Dimopoulos MA,Bamias A,et al.Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand(RANKL)/osteoprotegerin (OPG)axis in patients with solid tumors metastatic to the skeleton.Acta Oncol,2007,46:221-229
  • 6Boyce BF,Xing L.The RANKL/RANK/OPG pathway.Curr Osteoporos Rep,2007,5:98-104
  • 7Boyle WJ,Simonet WS,Lacey DL.Osteoclast differentiation and activation.Nature,2003,423(6937):337-342
  • 8Hsu H,Lacey DL,Dunstan CR,et al.Tumot necrosis factor receptor family memher RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.Proc Natl Acad Sci USA,1999,96:3540-3545
  • 9Armstrong AP,Tometsko ME,Glaccum M,et al.A RANK/TRAF6-depedent signal transduction pathway is essantial for osteoclast cytoskeletal organization and resorptive function.J Biol Chem,2002,277:44347-44356
  • 10Xu D,Wang S,Liu W,et al.A novel receptor activator of NF-κB (RANK)cytoplasmic motif plays an essential role in osteoclastogenesis by committing macrophages to the osteoclast lineage.J Biol Chem,2006,281:4678-4690

共引文献8

同被引文献35

  • 1Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN- 0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.Cancer, 2003, 97: 887-892.
  • 2Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo- controlled study of AMG 162, a fully human monaclonal antibody to RANKL, in postmenopausal women. 2004. J Bone Miner Res, 2005, 20: 2275-2282.
  • 3Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase Ⅱ study of denosnmab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol, 2007, 25: 4431-4437.
  • 4Fizazi K, Lipton A, Mariette X, et al. Randomized phase Ⅱ trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol, 2009, 27: 1564-1571.
  • 5Bolzoni M, Abehino M,Storfi P, et al. The immunomodulatory drugs lenalidomide and pomalidomide inhibit muhiple myeloma-induced osteoclast formation and rankl/opg ratio in myelama targeting the expression of adhesion molecules.Blood (ASH Annual Meeting Astraets), 2010, 116: Abstract 4-48.
  • 6Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1 α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood, 2003, 102: 311-319.
  • 7Oyajobi BO, Frmlchin G. CCR1 blockade by an orally-available CCR1 antagonist reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood(ASH Annual Meeting Abstract) 2010; 116:Abstract 3000.
  • 8Wright LM, Maloney W, Yu X, et al. Stromal cell-derived factor-I binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoblasts. Bone, 2005, 36: 840-853.
  • 9Menu E, Asosingh K, lndraccolo S, et al. The involvement of stromal derived factorla in homingand progression of multiple myeloma in the 5TMM model. Haematologica, 2006, 91: 605.
  • 10Barn R, Pennisi A, Li X, et al. Bruton's tyrosine kinase (BTK) is indispensable for myeloma cell migration towards SDF-I and induction of asteoclastogenesis and osteolytic bone disease. Blood (ASH Annual Meeting Abstracts), 2010, 116: Abstract:447.

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部